{"classes":[{"categories":[{"measurements":[{"comment":"NA=DOR upper limit not reached at time of data cutoff due to insufficient number of responding participants with relapse","groupId":"OG000","lowerLimit":"3.0","upperLimit":"NA","value":"16.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"For participants who demonstrate a confirmed complete response (CR: disappearance of target and non-target lesions and normalization of tumor markers) or confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR was based on modified RECIST for MPM as assessed by investigator.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with pemetrexed 500 mg/m\\^2 IV and cisplatin 75 mg/m\\^2 IV for 4-6 cycles, followed by pembrolizumab 200 mg/m\\^2 IV monotherapy Q3W for up to 35 cycles from the first dose of the study treatment (approximately 2 years). Each cycle was 21 days.","id":"OG000","title":"Pembrolizumab + Pemetrexed + Cisplatin"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least 1 dose of study intervention and demonstrated a confirmed response (CR or PR)","reportingStatus":"POSTED","timeFrame":"Up to approximately 31 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}